Analysis on the figures used in this article: TGA updates post-COVID vaccine myocarditis rates

“The updated figures, current as of 14 November, mean there have been 329 reports of likely myocarditis from approximately 23.4 million doses of Pfizer and 978,000 Moderna doses.

A further 592 cases have been identified as ‘suspected myocarditis’, including 116 in children aged 12–17, while there have been 1370 cases of suspected pericarditis only.” 

“The youngest case classified as likely myocarditis to date was 12 years old.

Being infected with COVID-19 itself is ‘associated with a substantially higher risk of myocarditis and other cardiac complications compared to the COVID vaccines’.

The relatively low number of Moderna doses administered in Australia to date means the TGA is unable to provide a reliable estimated rate of myocarditis following vaccination. However, it has provided the below table in relation Pfizer, which breaks down the rates between age groups and sexes.

Rates of myocarditis cases following Pfizer 

Age (years) All doses Second doses  
Rate per 100,000 doses Rate per 100,000 doses  
  Male Female Male Female  
12–17 5.6 1.3 8.5 2.3  
18–29 3.1 1.2 3.7 1.5  
30–39 1.4 0.6 1.5 0.6  
40–49 0.7 0.8 1.2 1.1  
50–59 0.4 0.4 0.1 0.4  
60–69 0.0 0.4 0.0 0.0  
70+ 0.0 0.2 0.0 0.0  
All ages 2.1 0.9 2.7 1.1  

 

The table shows suspected myocarditis following a second dose of Pfizer occurs at a rate of 8.5 cases per 100,000 in boys aged 12–17, more than three times higher than the overall rate among all males of 2.7 per 100,000.

Boys aged 12–17 are also more than twice as likely to develop suspected myocarditis following a first Pfizer dose (5.6 per 100,000) than the general male population. Both of the 12–17 age group figures are an increase on the rates contained in the most previous TGA safety report (5.2 and 7.1 cases per 100,000 first and second doses, respectively).”

https://www1.racgp.org.au/newsgp/clinical/tga-updates-post-covid-vaccine-myocarditis-rates

My calculations’ on the above; both myocarditis and pericarditis: 329+592+1,370 = 2,291. Now when you X this by 90 times you get 206,190. 

Remember there has been many studies that have stated that only 1 to 10 per cent are reported in the adverse reactions’ recording system and even that might be more than actually is reported. 

Underreporting and Post-Vaccine Deaths in the Vaccine Adverse Event Reporting System (VAERS) Explained https://medium.com/microbial-instincts/underreporting-and-post-vaccine-deaths-in-vaccine-adverse-event-reporting-system-vaers-explained-14fe22b2a65f

VAERS Admits Fewer Than 1% of Vaccine Adverse Events are Reported https://www.theburningplatform.com/2021/10/26/vaers-admits-fewer-than-1-of-vaccine-adverse-events-are-reported/

Australian Influenza Surveillance Report and Activity Updates https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-ozflu-flucurr.htm

Now the vaccination people there are 23.4 million doses of Pfizer and 978,000 Moderna doses. = 3,278,000 vaccines. 

So I divided this 3,278,000 by 1.50 people that have had their second dose, guessing that might be the nearest figure, and that was 2,185,334 and then divided by 206,190 into 2,185,334 = 10.44% of the people have been injured by the jab.  

Date: 18-12-21

Using CMS Whistleblower Data to Approximate the Under-Reporting Factor for VAERS

“What is the exact under-reporting factor?” Perhaps there is no way to determine it with foolproof accuracy, but there are previous studies which have estimated it, such as the Lazarus study of 2011. More recently, Kirsch/Rose/Crawford have estimated it at 41x based on comparing anaphylaxis rates published in a study to rates found in VAERS” 

https://vaersanalysis.info/2021/12/13/using-cms-whistleblower-data-to-approximate-the-under-reporting-factor-for-vaers/

Kevin: 329+592+1,370 = 2,291 Now 41x = 93,931.

2,185,334 and then divided by 93,931 = 23. 27% have myocarditis and pericarditis

Therefore, the propaganda is unbelievable. Please wake up!!!!!!!!!!!!!!!!!!!!!!!!!!!!!

Leave a Reply

Your email address will not be published.